Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the Invesco Biotechnology & Genome ETF (PBE), a passively managed exchange traded fund launched on June 23, 2005.

Passively managed ETFs are becoming increasingly popular with institutional as well as retail investors due to their low cost, transparency, flexibility and tax efficiency. They are excellent vehicles for long term investors.

Sector ETFs are also funds of convenience, offering many ways to gain low risk and diversified exposure to a broad group of companies in particular sectors. Healthcare - Biotech is one of the 16 broad Zacks sectors within the Zacks Industry classification. It is currently ranked 9, placing it in bottom 44%.

Index Details

The fund is sponsored by Invesco. It has amassed assets over $260.13 million, making it one of the average sized ETFs attempting to match the performance of the Healthcare - Biotech segment of the equity market. PBE seeks to match the performance of the Dynamic Biotechnology & Genome Intellidex Index before fees and expenses.

The Dynamic Biotech & Genome Intellidex Index seeks to provide capital appreciation by thoroughly evaluating companies based on a variety of investment merit criteria, including price momentum, earnings momentum, quality, management action, and value.

Costs

When considering an ETF's total return, expense ratios are an important factor, and cheaper funds can significantly outperform their more expensive counterparts in the long term if all other factors remain equal.

Annual operating expenses for this ETF are 0.58%, making it on par with most peer products in the space.

It has a 12-month trailing dividend yield of 1.03%.

Sector Exposure and Top Holdings

While ETFs offer diversified exposure, which minimizes single stock risk, a deep look into a fund's holdings is a valuable exercise. And, most ETFs are very transparent products that disclose their holdings on a daily basis.

This ETF has heaviest allocation in the Healthcare sector -- about 100% of the portfolio.

Looking at individual holdings, United Therapeutics Corp (UTHR) accounts for about 6.33% of total assets, followed by Illumina Inc (ILMN) and Regeneron Pharmaceuticals Inc (REGN).

The top 10 holdings account for about 48.13% of total assets under management.

Performance and Risk

Year-to-date, the Invesco Biotechnology & Genome ETF has added about 2.65% so far, and is up roughly 30.09% over the last 12 months (as of 06/10/2026). PBE has traded between $63.376 and $85.733 in this past 52-week period.

Story Continues

The ETF has a beta of 0.72 and standard deviation of 19.77% for the trailing three-year period, making it a high risk choice in the space. With about 33 holdings, it has more concentrated exposure than peers.

Alternatives

Invesco Biotechnology & Genome ETF carries a Zacks ETF Rank of 3 (Hold), which is based on expected asset class return, expense ratio, and momentum, among other factors. Thus, PBE is a good option for those seeking exposure to the Health Care ETFs area of the market. Investors might also want to consider some other ETF options in the space.

iShares Biotechnology ETF (IBB) tracks Nasdaq Biotechnology Index and the State Street SPDR S&P Biotech ETF (XBI) tracks S&P Biotechnology Select Industry Index. iShares Biotechnology ETF has $7.87 billion in assets, State Street SPDR S&P Biotech ETF has $8.01 billion. IBB has an expense ratio of 0.44%, and XBI charges 0.35%.

Bottom Line

To learn more about this product and other ETFs, screen for products that match your investment objectives and read articles on latest developments in the ETF investing universe, please visit Zacks ETF Center.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Invesco Biotechnology & Genome ETF (PBE): ETF Research Reports

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Investoren im Gesundheitssektor können zwischen der Stabilität von etablierten Gesundheitsriesen und dem hohen Wachstumspotenzial von innovativen Unternehmen wählen. Der State Street Health Care Select Sector SPDR ETF (XLV) bietet eine passive, kostengünstige Ausrichtung an etablierte Gesundheitsriesen, während der Simplify Health Care ETF (PINK) ein aktives Management konzentriert auf medizinische Durchbrüche anbietet.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Investing.com -- J.P. Morgan hat die Abdeckung von 14 großen Biotechnologieunternehmen wieder aufgenommen, wobei der Sektor ein wichtiger Wendepunkt erreicht habe, da Erfolge in den Pipelines zunehmend zu profitablen und diversifizierten Geschäftsunternehmen führen.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Für Investoren interessante Biotech-Aktien. Die Analysten Stephen Ayers und Petri Dish Reports von Seeking Alpha stellen ihre Empfehlungen vor. Sie nennen Insmed, Cogent Biosciences, Structure Therapeutics, ImmunityBio, Travere Therapeutics und Relay Therapeutics als potenziell attraktive Biotech-Aktien.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Investing.com -- JPMorgan hat die Bewertungen und Preisziele für 14 großen Kapitalbeteiligungen in der Biotechnologie wieder aufgenommen. Der Sektor sei an einem kritischen "Wendepunkt" angelangt, da Erfolge im Pipeline-Modell immer häufiger zu profitablen Geschäftsfranchises führen.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Der Abschluss einer Earnings-Saison kann eine gute Zeit sein, um neue Aktien zu entdecken und herauszufinden, wie Unternehmen mit der aktuellen Geschäftsumgebung umgehen. Lassen Sie uns einen Blick auf Halozyme Therapeutics (NASDAQ:HALO) und den Rest der therapeutischen Aktien im Q1 werfen.

Die 11 therapeutischen Aktien, die wir verfolgen, berichteten über ein befriedigendes Q1. Als Gruppe haben sie die Analysten-Erwartungen um 15,6 % übertroffen.

In Anbetracht dieser Nachricht sind die Aktien der Unternehmen stabil geblieben und sind durchschnittlich seit den letzten Earnings-Ergebnissen um 3,2 % gestiegen.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Okay, here's a 600-word summary of the provided text, followed by a German translation:

Summary (600 Words)

This report analyzes the recent quarterly earnings results of several key pharmaceutical and biotechnology companies – Myriad Genetics, Novavax, United Therapeutics, Vertex Pharmaceuticals, and AbbVie – providing insights into their performance compared to analyst expectations and highlighting broader trends within the therapeutics industry.

Key Industry Trends: The sector is currently benefiting from advancements in precision medicine, particularly the integration of AI to improve drug development and diagnostics. Growing demand for treatments targeting rare diseases is another significant tailwind. However, the companies face challenges including increasing scrutiny around drug pricing, potential regulatory hurdles, and competition from larger, more established pharmaceutical giants.

Earnings Performance Overview: Overall, the 11 therapeutics stocks tracked reported a solid Q4, with collective revenues exceeding analyst consensus estimates by 7.1%. However, share prices experienced an average decline of 1.8% since the earnings release, indicating a market reaction driven by lingering concerns.

Company-Specific Analysis:

• Myriad Genetics (NASDAQ:MYGN): Reported flat revenue of $209.8 million, slightly exceeding expectations. The company’s strong performance in Hereditary cancer testing and Prolaris prostate cancer test volume growth, coupled with positive guidance, led to a significant stock increase of 6.8% post-earnings.
• Novavax (NASDAQ:NVAX): Delivered a remarkable quarter with revenues up 66.6% year-over-year, significantly outperforming analysts’ estimates. Despite a subsequent 18.7% drop in stock price, the company’s impressive revenue growth stands out.
• United Therapeutics (NASDAQ:UTHR): Experienced a weaker quarter compared to expectations, with a revenue miss of 2.5%. The stock rallied with a 19.9% increase since reporting, a seemingly counterintuitive reaction.
• Vertex Pharmaceuticals (NASDAQ:VRTX): Reported revenue growth of 9.5%, beating analyst estimates by 1.1%. However, the stock declined by 5.6% due to a miss in EPS estimates.
• AbbVie (NYSE:ABBV): Demonstrated strong revenue growth of 10% and a robust beat of analyst expectations, with a 7.4% stock drop since reporting.

Broader Market Context: The report shifts focus to the broader market dynamics at the end of 2025/early 2026. Initially, anxieties surrounding artificial intelligence and cryptocurrency were prominent, leading to a rotation towards safer assets. However, this shifted dramatically in Spring 2026 due to heightened geopolitical risk, specifically the US-Iran conflict, which became the dominant market driver, prioritizing stability and risk aversion.

Conclusion: The report emphasizes the importance of analyzing individual company earnings against the backdrop of broader market trends and industry headwinds. It highlights the volatility within the sector and the need for investors to carefully evaluate potential investment opportunities.

German Translation (approximately 600 words):

Zusammenfassung (600 Wörter)

Dieser Bericht analysiert die jüngsten Quartalsergebnisse mehrerer wichtiger Pharma- und Biotechnologieunternehmen – Myriad Genetics, Novavax, United Therapeutics, Vertex Pharmaceuticals und AbbVie – und bietet Einblicke in ihre Leistung im Vergleich zu Analystenschätzungen und beleuchtet gleichzeitig breitere Trends in der Therapeutikbranche.

Wichtige Branchentrends: Der Sektor profitiert derzeit von Fortschritten in der Präzisionsmedizin, insbesondere von der Integration von KI zur Verbesserung der Arzneimittelentwicklung und der Diagnostik. Die wachsende Nachfrage nach Behandlungen für seltene Krankheiten ist ein weiterer bedeutender Schub. Allerdings stehen die Unternehmen vor Herausforderungen, darunter zunehmende Bedenken hinsichtlich der Arzneimittelpreise, potenzieller regulatorischer Hürden und dem Wettbewerb durch größere, etabliertere Pharmaunternehmen.

Ergebnisergebnisse: Insgesamt berichteten die 11 von der Therapeutikbranche verfolgten Unternehmen über ein solides Q4, wobei die gesamten Einnahmen die Konsensschätzungen der Analysten um 7,1 % übertrafen. Die Aktienkurse sanken jedoch im Durchschnitt um 1,8 % seit der Veröffentlichung der Ergebnisse, was auf eine Marktreaktion hindeutet, die durch anhaltende Bedenken vorangetrieben wird.

Unternehmen-spezifische Analyse:

• Myriad Genetics (NASDAQ:MYGN): Berichtete Umsatzerlöse von 209,8 Mio. USD, leicht höher als erwartet. Die starke Leistung bei hereditären Krebsuntersuchungen und Prolaris-Prostatakrebs-Test-Volumina, zusammen mit positiver Prognose, führte zu einem deutlichen Anstieg der Aktienkurse um 6,8 % nach der Veröffentlichung.
• Novavax (NASDAQ:NVAX): Liefern ein bemerkenswertes Quartal mit Umsätzen, die im Jahresvergleich um 66,6 % stiegen, deutlich über den Analystenschätzungen. Obwohl die Aktie nach diesem Zeitpunkt um 18,7 % fiel, sticht die beeindruckende Umsatzsteigerung des Unternehmens hervor.
• United Therapeutics (NASDAQ:UTHR): Erlebte ein schwächeres Quartal im Vergleich zu den Erwartungen mit einem Umsatzrückstand von 2,5 %. Die Aktie stieg mit einem Anstieg von 19,9 % seit der Veröffentlichung, eine scheinbar widersprüchliche Reaktion.
• Vertex Pharmaceuticals (NASDAQ:VRTX): Berichtete Umsatzwachstum von 9,5 %, das Analystenschätzungen um 1,1 % übertraf. Die Aktie sank jedoch um 5,6 % aufgrund eines Fehlers bei den EPS-Schätzungen.
• AbbVie (NYSE:ABBV): Demonstrierte einen Umsatz von 16,62 Mrd. USD, ein Wachstum von 10 % im Jahresvergleich, und eine solide Übertreibung der Analystenschätzungen, wobei die Aktie um 7,4 % seit der Veröffentlichung fiel.

Breitere Marktdynamik: Der Bericht lenkt den Fokus am Ende von 2025/anfang 2026 auf die breiteren Marktdynamiken. Zunächst waren Ängste hinsichtlich künstlicher Intelligenz und Kryptowährungen von Bedeutung, was zu einer Rotation in sicherere Vermögenswerte führte. Diese Veränderung ereignete sich jedoch im Frühjahr 2026 aufgrund erhöhter geopolitischer Risiken, insbesondere des US-Iran-Konflikts, der zum vorherrschenden Marktdriver wurde und die Priorität auf Stabilität und Risikovermeidung legte.

Fazit: Der Bericht betont die Bedeutung der Analyse einzelner Unternehmensleistungen im Kontext breiterer Markttrends und Branchenrisiken. Er hebt die Volatilität in der Branche hervor und fordert Investoren auf, potenzielle Investitionsmöglichkeiten sorgfältig zu bewerten.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Company Logo

The market offers opportunities in targeted therapies, increasing CAR T-cell and monoclonal antibody use, personalized medicine, and infrastructure investments

Pediatric Neuroblastoma Treatment MarketPediatric Neuroblastoma Treatment Market·GlobeNewswire Inc.

Dublin, April 02, 2026 (GLOBE NEWSWIRE) -- The "Pediatric Neuroblastoma Treatment Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report provides a detailed analysis of market size, regional shares, competitor strategies, and trends.

The pediatric neuroblastoma treatment market has demonstrated substantial growth, increasing from $2.02 billion in 2025 to a projected $2.2 billion in 2026, at a CAGR of 9%. Historical growth factors include limited access to oncology drugs, low adoption of immunotherapy, reliance on conventional chemotherapy, limited specialized centers, and fragmented clinical data.

Looking forward, the market is expected to reach $3.13 billion by 2030, growing at a 9.2% CAGR. This growth is driven by enhanced R&D in targeted therapies, increased use of CAR T-cell and monoclonal antibodies, rising adoption of personalized medicine, and expanded investment in oncology infrastructure. Other growth catalysts include awareness programs for early detection, AI in diagnostics, genomics-based therapies, cloud and big data integration for patient management, IoT-enabled monitoring, and innovations in drug production.

The growing number of new neuroblastoma cases will significantly drive market expansion. The rising prevalence is fueling demand for effective treatments, motivating pharmaceutical companies to invest in R&D and foster innovation. Advanced diagnostics and screening technologies now allow for earlier neuroblastoma detection, supporting timely interventions and improved clinical outcomes. Data from the American Society of Clinical Oncology highlights that neuroblastoma affects 700 to 800 children annually in the US alone, accounting for 6% of all childhood cancers.

Leading companies are advancing technologies like antibody-based approaches, enhancing therapy effectiveness and patient outcomes. Renaissance Pharma Ltd introduced Hu14.18K322A, targeting GD2 on neuroblastoma cells, enhancing immune attack on tumors. Moreover, Serb Pharmaceuticals' acquisition of Y-mAbs Therapeutics aims to bolster its pediatric oncology portfolio, particularly through DANYELZA, a flagship anti-GD2 monoclonal antibody for high-risk cases.

Major market players include United Therapeutics Corporation, APEIRON Biologics AG, Pfizer Inc., MacroGenics Inc., Bayer AG, Y-mAbs Therapeutics Inc., Amgen Inc., Eli Lilly, F. Hoffmann-La Roche AG, Novartis AG, Johnson & Johnson, AbbVie Inc., Merck & Co., Bristol-Myers Squibb, Takeda Pharmaceutical, Daiichi Sankyo, and Eisai Co.

Story Continues

In 2025, North America led the market. Regions covered include Asia-Pacific, Europe, North and South America, the Middle East, and Africa. Countries in focus include the US, UK, Germany, France, China, India, and Japan.

Reasons to Purchase:

Gain a comprehensive global perspective by exploring 16 geographical markets. Analyze macro factors such as geopolitical issues, trade policies, inflation, interest rate shifts, and regulatory changes. Formulate regional and country-level strategies based on local insights. Pinpoint investment opportunities in growth sectors. Utilize accurate forecast data to outperform market competitors. Enhance customer understanding through detailed end-user analysis. Benchmark against major competitors using market share, innovation metrics, and brand analysis. Calculate the total addressable market (TAM) and assess its attractiveness. Support presentations with reliable data and analysis. Receive updates with the newest data accompanied by an Excel data sheet for robust analysis. Access data through an interactive Excel dashboard.

Report Scope:

Markets Covered: By Treatment Type: Immunotherapy, Chemotherapy, Radiation Therapy, Other Treatments Risk Groups: Low, Intermediate, High End Users: Hospitals, Specialty Clinics

Companies: United Therapeutics Corporation, APEIRON Biologics AG, Pfizer Inc., Bayer AG, Amgen Inc., Novartis AG, and more.

Countries: Australia, Brazil, China, France, India, Japan, Taiwan, UK, USA, among others.

Regions: Asia-Pacific, Western Europe, North America, Middle East, Africa

Time Series: Five years historic and ten years forecast.

Key Attributes

Report Attribute Details No. of Pages 250 Forecast Period 2026-2030 Estimated Market Value (USD) in 2026 $2.2 Billion Forecasted Market Value (USD) by 2030 $3.13 Billion Compound Annual Growth Rate 9.2% Regions Covered Global

The companies featured in this Pediatric Neuroblastoma Treatment market report include:

United Therapeutics Corporation APEIRON Biologics AG Cell Ectar Biosciences Inc. Pfizer Inc. MacroGenics Inc. Bayer AG Provectus Biopharmaceuticals Inc. Y-mAbs Therapeutics Inc. Amgen Inc. Eli Lilly and Company F. Hoffmann-La Roche AG Clarity Pharmaceuticals CureSearch for Children's Cancer Novartis AG Johnson & Johnson Services Inc. AbbVie Inc. Merck & Co. Inc. Bristol-Myers Squibb Company Takeda Pharmaceutical Company Limited Daiichi Sankyo Company Limited Eisai Co. Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/wahoih

About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

Pediatric Neuroblastoma Treatment Market

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.

The Morning Bull - US Market Morning Update Tuesday, Mar, 31 2026

US stock futures are pointing higher this morning, with E mini S&P 500 contracts up about 0.8% and Nasdaq 100 futures showing a similar gain. The backdrop is a sharp rise in government borrowing costs across Europe, where 10 year bond yields in the UK and Italy have jumped as investors worry that the Iran conflict and higher oil prices could keep inflation alive. At the same time, US 10 year yields have eased to around 4.32% after cautious comments from the Federal Reserve chair. The tension for investors is clear: do rate sensitive areas like banks, real estate and smaller stocks benefit more from calmer US yields, or does the bond shock in Europe and energy pressure keep defensive sectors such as utilities in focus?

Worried about rate shocks and inflation staying sticky? Focus on 62 resilient stocks with low risk scores before volatility widens further.

Top Movers

United Therapeutics (UTHR) jumped 12.53% after its TETON 1 IPF study met the primary efficacy endpoint. ServiceNow (NOW) gained 5.59% alongside strength in software names focused on enterprise workflow automation. Insmed (INSM) rose 5.52% after an upgrade at Morgan Stanley and a recent price target increase.

Is Insmed still a smart investment or just hype? Read our most popular narrative and get all the answers you need.UTHR 1-Year Stock Price Chart

Top Losers

Sysco (SYY) declined 15.28% after agreeing to acquire Jetro Restaurant Depot for about US$29b. Fabrinet (FN) declined 10.89%. Astera Labs (ALAB) declined 10.85%.

Look past the noise - uncover the top narrative that explains what truly matters for Sysco's long-term success.SYY 1-Year Stock Price Chart

On The Radar

Earnings from a major consumer brand and shifting global bond markets will share the spotlight over the next few sessions.

Consumer bellwether:NIKE (NKE) reports Q3 results on Tuesday, providing a clear view of global discretionary demand. Global rates check: Surging UK and euro area 10 year yields continue to influence valuations and sector preferences through Thursday. US data pulse: March consumer confidence and JOLTS on Tuesday offer a closer look at demand and labor market tightness. Policy tone: Recent Fed chair comments, together with firm overseas yields, frame the debate on the duration of restrictive policy.

Use our Portfolio or Watchlist features to track market-moving events like these and get alerts for the companies you own, free!

Build Your Perfect Portfolio

When headlines feel noisy and short term, it helps to focus on quality that can hold up when conditions change quickly, and the clock is already ticking to get familiar with the solid balance sheet and fundamentals stocks screener (39 results). These companies pair sturdier balance sheets with fundamentals your future self may thank you for taking seriously today.

Story Continues

Ready to take control of your next move? Our stock screener lets you run custom searches that fit your style and set timely alerts so you never miss fresh opportunities as they appear.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Insmed INSM shares rallied 5.5% in the last trading session to close at $153.32. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 2.7% loss over the past four weeks.

This rise in share price likely in response to the positive data from a late-stage study reported by rival United Therapeutics. This study achieved its primary endpoint — treatment with Tyvaso for 52 weeks demonstrated superiority over placebo by improving absolute forced vital capacity (FVC) by 130.1 mL in patients with idiopathic pulmonary fibrosis (IPF). FVC measures lung health by quantifying how much air a patient can forcefully exhale after taking a deep breath.

Insmed is developing treprostinil palmitil inhalation powder (TPIP), a prodrug version of treprostinil — the active ingredient used in United Therapeutics’ Tyvaso. As a prodrug, TPIP remains inactive until metabolized in the body, enabling a more gradual release of treprostinil. This extended-release design enables once-daily dosing, compared to Tyvaso, which requires multiple daily doses using either a nebulizer or a dry powder inhaler. Insmed remains on track to start a late-stage study on TPIP in IPF in the second half of 2026.

While the Tyvaso data relates to a competing therapy, it provides an encouraging, though indirect, read-through by validating the therapeutic potential of treprostinil in IPF — a space with historically limited treatment success. However, TPIP’s efficacy and safety in this indication remain to be established in late-stage studies.

This biopharmaceutical developing inhaled treatments for patients battling rare lung diseases is expected to post quarterly loss of $1.00 per share in its upcoming report, which represents a year-over-year change of +29.6%. Revenues are expected to be $299.57 million, up 222.7% from the year-ago quarter.

While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

For Insmed, the consensus EPS estimate for the quarter has been revised marginally higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on INSM going forward to see if this recent jump can turn into more strength down the road.

The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

Story Continues

Insmed is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, Keros Therapeutics, Inc. KROS, finished the last trading session 0.7% higher at $10.68. KROS has returned -25.2% over the past month.

Keros Therapeutics' consensus EPS estimate for the upcoming report has changed -85.8% over the past month to -$1.02. Compared to the company's year-ago EPS, this represents a change of -128.2%. Keros Therapeutics currently boasts a Zacks Rank of #3 (Hold).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Insmed, Inc. (INSM) : Free Stock Analysis Report

Keros Therapeutics, Inc. (KROS) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

View Comments